Browse Studies — Arctuva

Phase 1

A Randomized, Double-Masked, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ETHY-001

The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and partici…

Thyroid Eye Disease (TED)Graves' DiseaseEye Diseases, Hereditary+11 more

Estimated

~$500 – $10,500

Actual pay is set by the research site.

Ethyreal Bio, Inc.NCT07885605

Phase 1

An Adaptive Phase 1/2 MulticenteR Study Evaluating the Safety, Tolerability, Pharmacokinetics and EfficaCy of VV-14305 Delivered Via PeribuLbAr Injection in Patients With Moderate to Severe Thyroid Eye Disease (the RECLAIM Study)

The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).

Thyroid Eye Disease (TED)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Kriya Therapeutics, Inc.NCT07404111

Prospective Observational Study of Smartphone-Based Self-Monitoring Using an Artificial Intelligence Solution During Non-Surgical Treatment for Thyroid Eye Disease

This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system i…

Thyroid Eye Disease (TED)Graves OphthalmopathyThyroid Associated Ophthalmopathies

Estimated

~$10 – $1,050

Actual pay is set by the research site.

THYROSCOPE INC.NCT07623993